文献速递肝病消化道肿瘤与早癌

循环肿瘤细胞检测及其作为肝细胞癌诊断、预后与治疗监测生物标志物的意义

Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma.
PubMed 文献 · Hepatology · 2021-01-18

肝细胞癌(HCC)预后差主要因晚期才被发现,现有甲胎蛋白等标志物准确性有限,肝活检因有创和肿瘤种植风险不常规使用。液体活检中的循环肿瘤细胞(CTC)可通过外周血简单检测,有望用于HCC早期检测、预后判断、治疗反应预测和疾病监测。本文综述CTC检测与分离技术、在HCC临床管理中的效用、局限性和未来研究方向。

要点

  • CTC可通过外周血简单检测,潜在反映肿瘤整体特征。
  • CTC数量、生物学特征和基因组异质性可预测HCC预后和治疗反应。
  • CTC检测技术基于免疫亲和和生物物理特性,可高效识别和捕获CTC。

核心结论

  • CTC液体活检在HCC精准医疗中具有很大潜力,可辅助早期检测和管理。

研究设计与样本

  • 本文为综述,讨论CTC检测与分离技术及其在HCC临床管理中的应用、局限性和未来方向。

主要发现

  • CTC数量、生物学特征及CTC间基因组异质性可预测HCC患者疾病预后和治疗反应。

关键数值与推荐

  • 甲胎蛋白作为HCC诊断或预后标志物准确性有限。
  • 肝活检因有创性和肿瘤种植风险不常规使用,尤其早期患者。
  • 肝活检因瘤内异质性在揭示全面肿瘤生物学方面受限。

临床怎么用

  • CTC可通过简单外周血抽血检测,潜在展示肿瘤整体特征。
  • 基于免疫亲和和生物物理特性的多种CTC检测平台可高效识别和捕获CTC。

局限性

  • 原文提及综述将讨论CTC检测的局限性,但未具体列出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is among the leading causes of worldwide cancer-related morbidity and mortality. Poor prognosis of HCC is attributed primarily to tumor presentation at an advanced stage when there is no effective treatment to achieve the long term survival of patients. Currently available tests such as alpha-fetoprotein have limited accuracy as a diagnostic or prognostic biomarker for HCC. Liver biopsy provides tissue that can reveal tumor biology but it is not used routinely due to its invasiveness and risk of tumor seeding, especially in early-stage patients. Liver biopsy is also limited in revealing comprehensive tumor biology due to intratumoral heterogeneity. There is a clear need for new biomarkers to improve HCC detection, prognostication, prediction of treatment response, and disease monitoring with treatment. Liquid biopsy could be an effective method of early detection and management of HCC. Circulating tumor cells (CTCs) are cancer cells in circulation derived from the original tumor or metastatic foci, and their measurement by liquid biopsy represents a great potential in facilitating the implementation of precision medicine in patients with HCC. CTCs can be detected by a simple peripheral blood draw and potentially show global features of tumor characteristics. Various CTC detection platforms using immunoaffinity and biophysical properties have been developed to identify and capture CTCs with high efficiency. Quantitative abundance of CTCs, as well as biological characteristics and genomic heterogeneity among the CTCs, can predict disease prognosis and response to therapy in patients with HCC. This review article will discuss the currently available technologies for CTC detection and isolation, their utility in the clinical management of HCC patients, their limitations, and future directions of research.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Ahn JC, Teng PC, Chen PJ, et al. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology. 2021. PMID: 32017145. doi:10.1002/hep.31165

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。